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Abstract
Aim
Left ventricle (LV) regional fractional area change (RFAC) measured by cardiac magnetic
resonance (CMR) allows the non-invasive localization and quantification of the degree of
myocardial infarction (MI), and could be applied to assess the effectiveness of pharmaco-
logical or regenerative therapies. Here we investigate the ability of RFAC to identify regional
dysfunction and discriminate the effect of pharmacological treatment with valsartan, a selec-
tive antagonist of angiotensin II type 1 receptor, in a model of MI.
Methods and Results
C57BL/6N mice, undergoing coronary artery ligation, were divided into two groups:
untreated (MI) or treated with valsartan (MI+Val). Sham-operated mice were used as a con-
trol. Cardiac dimensions and function were assessed at baseline, 24 hours, 1 and 4 weeks
post surgery by CMR and echocardiography. At sacrifice histology and whole-genome
gene expression profiling were performed. RFAC was able to detect significant differences
between treatment groups whereas the global ejection fraction was not. RFAC showed
greater loss of regional contraction in remote non-infarcted myocardium in MI group than in
MI+Val group. Consistently, in the same region MI+Val mice showed reduced myocyte
hypertrophy, fibroblast proliferation, and fibrosis and modulation of target genes; in addition,
left atrium volumes, appendage length and duct contraction were preserved.
Conclusion
In this study, RFAC effectively estimated the degree of systolic dysfunction and discrimi-
nated the regions preserved by pharmacological treatment. RFAC index is a promising tool
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to monitor changes in LV contraction and to assess the effectiveness of therapeutic regi-
mens in clinical settings.
Introduction
Myocardial infarction (MI) leads to complex structural alterations (remodeling) involving both
the infarcted and non-infarcted left ventricular (LV) myocardium characterized by chambers
dilatation, myocyte loss, fibroblast proliferation, scar formation [1, 2], and compensatory
hypertrophy. These conditions affecting LV wall stiffness are associated with worsening ven-
tricular systolic function and abnormal cardiac remodeling, and are responsible for the increase
in LV end-diastolic volume and pressure leading, consequently, to left atrial enlargement [3].
Clinical studies indicated fibrosis as the major independent predictive factor of adverse cardiac
outcome [4, 5]. Nevertheless, there are no specific strategies based on tissue characterization of
the myocardial wall in the therapeutic guidelines for post-ischemic heart failure. This lack of
specific treatment stems from the absence of accurate clinical tools for phenotyping patients
with heart disease and might lead to inappropriate therapies and possibly increased morbidity
[6].
Imaging techniques play a central role in the diagnosis of acute myocardial infarction
because of their ability to detect wall motion abnormalities or loss of viable myocardium. A
number of reports proved the advantages of cardiac magnetic resonance (CMR) as reference
tool for the non-invasive assessment of heart anatomy and function, advocating this approach
as both an efficient method to monitor and an instrument to improve the therapeutic options
[7–10]. CMR shows a high degree of accuracy in monitoring regional LV remodeling [11, 12],
enabling objective quantification of subtle impairment in regional myocardial function [13, 14]
and of pharmacological modulation on infarcted and viable myocardium.
Precise myocardial tissue characterization and a direct monitoring of treatment effects
might be of great help in developing optimal therapeutic strategies for post-MI LV remodeling.
Indeed, beneficial effects of pharmacological therapies on LV remodeling are associated with a
better prognosis in MI patients: this makes maladaptive remodeling, occurring on remote non-
infarcted myocardium, a therapeutic target for improving clinical outcome.
In the present study, we evaluated the power of regional fractional area change (RFAC)
computed from CMR images in monitoring the effect of valsartan, an angiotensin II type 1
receptor (AT1R) antagonist, on LV remodeling in a mouse model of MI. RFAC is an index of
LV regional wall motion and contraction [15] and is used to (a) assess qualitatively and quanti-
tatively LV regional loss of function in infarcted and non-infarcted myocardium and (b) esti-
mate drug effects occurring on myocardial wall motion. Imaging data were substantiated by
tissue composition analysis and whole-genome gene expression profiling. Echocardiographic
evaluation of left atrium (LA) volume was additionally used as index of LV performance and to
indirectly monitor the LV diastolic function [16].
Methods
Animals
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiments of the University of Milan
(approval number 1242003—A 1371072003). Animals were fed ad libitum with standard chow
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and water. All surgery was performed under anesthesia, and all efforts were made to minimize
the number of animals used and their suffering.
A total of 60 C57BL/6N female mice of 8–10 week old, weighting 18–20 g, purchased from
Charles River (Calco, Italy), were used.
Experimental protocol
Mice were anesthetized by intraperitoneal injection of a mixture of ketamine (75 mg/Kg) and
medetomidine hydrochloride (1 mg/kg), endotracheally intubated in a supine position with a
steel tube and ventilated with positive airway pressure (tidal volume of 140 μl at 150 breaths/
min). After baseline CMR and echocardiography, MI was induced by left anterior descending
(LAD) coronary artery ligation (n = 48), as previously described [17]. As control of surgery
procedure, sham operated mice underwent thoracotomy and pericardiotomy without coronary
artery ligation (n = 12). After surgery atipamezolo (2.5 mg/kg) was administered to encourage
animal awakening, and then the animals were extubated, placed on an heating pad regulated to
38.5°C, and their breathing function monitored every 30 minutes until they were completely
awake (usually in 2 hours).
After LAD ligation, surviving mice with an ejection fraction (EF) at 24-hour CMR within
the range 35–45% were selected and randomized to vehicle or valsartan. Mice dying during the
study or with unreliable measurements were replaced to obtain two final, equally-sized experi-
mental groups of infarcted untreated (MI, n = 12) and treated (MI+Val, n = 12) animals.
Valsartan was administered in drinking water at the dose that did not influence systolic
blood pressure (1 mg/Kg/day) [18, 19]. Drug was dissolved in distilled water at 10 mg/ml
according to the manufacturer’s instructions and then diluted daily at the selected dose with a
small amount (1 ml) of drinking water. After consumption of this small amount, the animals
were given free access drinking water.
At 24 hours, 1 and 4 weeks after surgery, CMR was performed to evaluate LV parameters
while echocardiography for LV, LA, and left atrial appendage (LAA) analysis (no LA and LAA
quantification was possible by CMR for lack of both spatial and temporal resolution). Blood
pressure was measured at the follow-up. Water consumption and body weight (BW) were care-
fully monitored during the follow-up. At sacrifice histological (n = 6/group) and genomic
(n = 6/group) analyses were performed.
Cardiac magnetic resonance
Induction of anesthesia was accomplished by exposing mice to 2% isoflurane (Merial, Tou-
louse, France) in 100% oxygen in an induction chamber. Mice were then fixed on a holder,
anesthetized with inhaled 1% isoflurane in 100% oxygen, and placed into the 3.8 cm coil. Tem-
perature was monitored rectally. The images were acquired using a 4.7T vertical-bore MR mag-
net (Bruker, Germany) and a retrospective gated cine gradient echo sequence with the
following parameters: echo time (TE) 1.9 ms; repetition time (TR) 10 ms; field of view 4 × 4
cm2; acquisition matrix 128 × 128 pixels; slice thickness 1.3 mm; 6–8 axial slices spaced 1 mm
to fully cover the LV.
The magnetic resonance images were analyzed using custom software implemented in
Python along the lines of Franzosi et al. [12], to obtain LV global parameters as end-diastolic
(LV EDV), end-systolic (LV ESV) and stroke volumes (LV SV), ejection fraction (LV EF) and
posterior diastolic wall thickness (LV PWth). For the quantitative analysis of regional function
and wall contraction, the LV cavity was divided into six 60° sectors (anterior, antero-septal,
septal, lateral, posterior and inferior): RFAC was then computed for each segment as [(end dia-
stolic area—end systolic area)/end diastolic area × 100] and used as index of regional
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endocardial wall motion [20]. Regional LV wall motion was displayed in a "bull’s eye" format,
where the red tones represent lower and the green tones higher values. In this plot the inner cir-
cle represents the LV apex and the outer ones represent consecutive slices from apex to the
base. To average the RFAC in mice with a different number of slices covering the LV, RFAC
data were resampled using cubic spline interpolation to 10 slices for each of the six sectors.
Regional LV thickness was obtained as previously reported [12].
Echocardiography
Induction of anesthesia was accomplished by exposing the mice to 2% isoflurane in 100% oxy-
gen in an induction chamber. Transthoracic echocardiography was then performed using 1%
isoflurane in 100% oxygen to maintain heart rate (HR)450 beats per minute (bpm). During
acquisition animals were placed in the supine position on a heated (37°C) platform with inte-
grated electrode pads used to obtain electrographic signals and HR. The mouse chest area was
shaved and a warmed ultrasound gel applied to the thorax surface to optimize the visibility of
the cardiac chambers. A Vevo 2100 echocardiography system (VisualSonics, Toronto, Canada)
equipped with a MS400 30-MHz linear array transducer was used in these experiments.
LV cavity dimensions, ventricular function and mass were calculated on the M-mode para-
sternal short axis view. LA areas and longitudinal (supero-inferior, from the midpoint of the
mitral annulus to the superior wall) and transversal diameters (medio-lateral, from the intera-
trial septum to the LA lateral wall, using the upper border of the LA-LAA duct as a marker)
were measured on apical 4-chamber view, and minimum and maximum atrial volumes (LA
Vmin, LA Vmax) were computed by Simpson’s rule. LA emptying fraction (LA EF) was calcu-
lated as the difference between LA Vmax and LA Vmin, divided by LA Vmax. On the same
view the LAA maximum long axis (LAA length), as the mid-line curve between the LAA apex
and duct during LV end-systole, was measured and the minimum and the maximum duct
diameters assessed, in order to calculate duct diameter fractional shortening (LAA duct FS) as
[(maximum—minimum) / maximum × 100] [21].
Tail-cuff blood pressure and pulse measurements
Systolic arterial blood pressure and pulse were measured by tail-cuff plethysmography (BP-
2000 Blood Pressure Analysis System; Visitech Systems, Apex, NC). Three days of training ses-
sions were necessary to accustom animals to the procedure. Recording sessions (5 measure-
ments each) were then made by a single investigator, at the baseline and at the different time
points during the follow-up.
Tissue collection and section preparation
To prepare specimens for histological analysis, abdominal aorta was cannulated and heart was
arrested in diastole, with 2 mL of a solution of 0.1M CdCl2 and 1M KCl, and retrogradely per-
fused with 0.01 M phosphate saline buffer (PBS) and then with 4% (vol/vol) phosphate-buff-
ered formalin for 10 min each time. Hearts were collected and LAA removed; tissues were
postfixed in 4% phosphate-buffered formalin for 24 hours and separately embedded in paraf-
fin. Consecutive 8 μm heart axial (from base to apex) and LAA sections were prepared.
For transcriptome analysis, hearts were perfused with PBS and the portion of the non-
infarcted free wall corresponding to the posterior and inferior sectors was collected in RNAla-
ter (Life Technologies, Carlsbad, CA) and stored at -80°C.
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Histological determination of infarct size
For collagen staining, deparaffinized and rehydrated heart sections were incubated in 0.1% Sir-
ius Red Solution (Direct Red 80, Sigma-Aldrich, St. Louis, MO) in picric acid for 30 min, then
washed, dehydrated (1 min each in 70%, 96%, and absolute ethylic alcohol, and then 10 min in
xylene), and mounted with DPX mountant for microscopy. Images were acquired with a high-
resolution digital camera using 1:1 macro-lens. Myocardial infarct size was determined on LV
axial section (one for each mm on LV) along the apex-basis axis and expressed as percentage of
the length of the infarct scar on the LV total circumferential length (using the average of endo-
cardial and epicardial tracings) using the ImageJ v. 1.44o software.
Immunostaining for morphometry, collagen, and cell proliferation
Immunofluorescence staining was performed on 3 tissue sections from each heart in order to
assess myocyte cross-sectional area (MCSA), interstitial collagen fraction (ICF), and cell prolif-
eration. Deparaffinized and rehydrated heart sections were incubated at room temperature in
10% normal goat serum (Dako, Glostrup, Denmark) in 0.01 M PBS and 0.1% Triton X-100 for
45 min. Primary and secondary antibodies were prepared in PBS and 0.1% Triton X-100. To
detect cardiomyocytes, fibroblasts, myofibroblasts, collagen I deposition, and cell proliferation
the sections were incubated overnight at 4°C respectively with anti-α-sarcomeric actin (1:800),
anti-vimentin (1:1500), anti-α-SMA mouse monoclonal antibodies (1:400; all previous from
Sigma-Aldrich, St. Louis, MO), anti-collagen type I (1:50, Rockland, Gilbertsville, PA), and
anti- Ki-67 rabbit polyclonal antibodies (1:100, Novocastra Laboratories, Newcastle, UK).
Appropriate secondary antibodies (Alexa 555 goat anti-mouse IgM or IgG [1:600] and Alexa
488 goat anti-rabbit [1:400], all from Invitrogen, Carlsbad, CA) were applied for 2 h at room
temperature. For nuclear staining, the sections were incubated with Hoechst 33258 (2.5 g/ml;
Invitrogen) in PBS for 15 min. Images were acquired at fixed exposure times using an inverted
fluorescence microscope (Axiovert 200; Zeiss, Jena, Germany) equipped with the Axiovision v.
3.1 software (Zeiss).
MCSA was assessed on LV tissue sections, double-labeled with anti-α-sarcomeric actin and
anti-collagen type I: cardiomyocytes cut along the short axis, showing a circular profile and a
visible nucleus were selected and their area was traced. ICF was measured within the LV non-
infarcted zone and LAA and expressed as percentage of area occupied by collagen on total tis-
sue area. Proliferating fibroblasts in LV remote non-infarcted myocardium were detected by
double labeling with anti-Ki-67 as marker of proliferation and anti-vimentin as marker of
fibroblasts. Cell proliferation was expressed as percentage of Ki-67 positive cells over the total
number of cells (counting the nuclei); the rate of fibroblasts proliferation was expressed as a
percentage of vimentin/Ki-67 double-positive cells over vimentin positive cells. Measurements
were performed on 5 and 10 fields per section (220μm × 165 μm) for ICF and cell proliferation,
respectively, whereas MCSA was based on 100 measured cardiomyocytes. All quantitative anal-
yses were performed using Photoshop CS6 by an investigator blinded for the experimental
groups.
Gene Expression Analysis
Total RNA was isolated from LV non-infarcted free wall using the TRIzol Reagent (Life Tech-
nologies) and further purified using silica-membrane RNeasy spin columns (Qiagen, Hilden,
Germany), following the manufacturers' instructions. Genomic DNA contamination was
removed by TURBO DNA-free DNase (Life Technologies) treatment. Messenger RNA was
reverse transcribed, labeled, and linearly amplified using the Total Prep RNA Amplification
Kit (Life Technologies), and then hybridized to MouseWG-6 v.2 Expression BeadChip
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microarrays (Illumina, San Diego, CA), according to the manufacturers' instructions. Signal
detection was performed using a high resolution confocal scanner iScan, and quantitation and
quality control were performed with the GenomeStudio v. 1.9.0 software (Illumina).
Data adjustment, probe filtering, gene annotation and primary statistical analysis were per-
formed using BRB-Array Tools v. 4.3.2, developed by Dr. Richard Simon and BRB-Array Tools
Development Team, and software packages of Bioconductor v. 2.12 and R v. 3.0.1. Data vari-
ance stabilizing transformation (VST) and robust spline normalization (RSN) were conducted
with the lumi R package. To focus on the most informative probes and genes, we used the fol-
lowing filtering criteria: a probe was excluded if (a) the 33th percentile of intensities was less
than 125 (corresponding to a detection p-value less than 0.01, as reported by GenomeStudio)
and/or (b) the p-value of the log-variation was greater than 0.05; (c) multiple probes were
reduced to one per gene symbol by using the most variable probe measured by interquartile
range across arrays. The number of genes that passed these filtering criteria was 8633. Differen-
tially expressed genes among the three classes were identified by using a multivariate permuta-
tion test, based on 1000 random permutations, to provide 80% confidence (CI) that the false
discovery rate (FDR) was less than 10%. The test statistics used was F-statistics for each gene;
nonetheless, the multivariate permutation test is non-parametric and does not require the
assumption of Gaussian distributions. We then performed a pairwise comparison (t-test)
between pairs of classes, setting α = 0.01 for significantly different gene expression. Finally, to
focus on the most meaningful differences, we filtered out those genes with a mean fold change
(FC) ±1.2 in any of the two relevant post-hoc comparisons (i.e., MI vs. Sham and MI vs. MI
+Val).
To identify clusters of genes with distinct expression patterns between the three conditions,
we used the CLICK (CLuster Identification via Connectivity Kernels) clustering algorithm,
implemented in the EXPANDER v. 6.3 (EXPression ANalyzer and DisplayER) software pack-
age [22] with the default homogeneity parameter 0.65 for a balanced intra-cluster similarity
and inter-cluster separation. Functional enrichment analysis was performed using the TANGO
(Tool for ANalysis of GO enrichments) algorithm, integrated in EXPANDER. The algorithm
performs hyper-geometric enrichment tests for Gene Ontology (GO) terms (in biological pro-
cess andmolecular functions ontologies) and corrects for multiple testing by bootstrapping
(1000 bootstraps), estimating the empirical p-value distribution for the evaluated sets. A func-
tional class was considered significantly enriched in a cluster if its corrected p-value was lower
than 0.05.
To identify genes whose expression was significantly related to RFAC, we computed a statis-
tical significance level for each gene using the Pearson’s correlation test. These p-values were
then used in a multivariate permutation test in which the RFACs were randomly permuted
among arrays. We used the multivariate permutation test to provide 80% confidence that the
FDR was less than 10%.
The data discussed in this publication have been deposited in NCBI's Gene Expression
Omnibus [23] and are accessible through GEO Series accession number GSE68426.
Statistical analysis
Statistical analyses were performed using R: A Language and Environment for Statistical Com-
puting (R Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2013, http://
www.R-project.org). Values are shown as mean ± SEM (standard error of the mean), unless
indicated; p<0.05 was considered significant. For measurements at the 24-hour time point, i.e.
before pharmacologic treatment, we performed an ANOVA with Helmert contrast comparing
(a) the sham group to the average of the MI and MI+Val groups, to assess that surgery was
RFAC in Myocardial Infarction
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effective, and (b) MI group to MI+Val group, to assess that the assignment was unbiased. For
measurements after the pharmacologic treatment (1 and 4 weeks), ANOVA with "treatment"
contrast was performed to compare MI group either with MI+Val or sham group. Repeated
measures ANOVA with post-hoc Holm adjustment was performed on the sham group to
assess time constancy. RFAC values of MI and MI+Val groups were compared, sector by sector
and slice by slice (on the resampled 10-slice space), using unpaired t-test. Mid-apical RFAC
values were also averaged by sector excluding the apex slice (unreliable due to apex movement,
which causes partial volume artifacts) and the three at the base end of the heart not affected by
infarction. Finally, Kaplan-Meier survival curves and the log-rank test were used to compare
the mortality rate among groups after randomization to treatment with valsartan.
Results
Mortality, body weight and systolic blood pressure
Of the 48 mice that underwent LAD ligation (Fig 1) 8 died before 24 hours, 10 were excluded
because their EF was out of 35–45% range at 24-hour CMR, 2 were excluded because surgery
scar prevented correct Echo measurements, and 4 died within 1 week after randomization (3
MI and 1 MI+Val). No other death was observed in the remaining follow-up period. All 12
sham-operated mice survived during the follow-up period. No significant differences in mor-
tality rate were observed among the three study groups after randomization to treatment.
Mice BW, following an initial decrease immediately after surgery, tended to increase during
the follow-up period without significant differences among the experimental groups at 4 weeks
(sham: 21.6 ± 0.3 g; MI: 22.8 ± 0.4 g; MI+Val: 22.3 ± 0.4 g).
No significant difference was found in heart rate (ranging 590–640 bpm) and in systolic
blood pressure among the three groups at follow-up (baseline: 102 ± 4 mmHg; 4 weeks post-
surgery: sham: 110 ± 2 mmHg; MI: 111 ± 7 mmHg; MI+Val: 118 ± 6 mmHg).
Cardiac function
During the follow-up period ventricular parameters in sham-operated mice remained
unchanged compared to baseline, whereas in MI and in MI+Val mice LV EDV and LV ESV
increased steadily exhibiting severe LV dilatation and a large significant reduction in LV EF
(Table 1). Nevertheless, LV SV remained almost unchanged at follow-up compared to baseline
(baseline: 27 ± 1 μl; 4 weeks post-surgery sham: 33 ± 1 μl; MI: 30 ±2 μl; MI+Val: 27 ±1 μl).
As shown in Table 1, when compared to MI group, MI+Val mice showed an attenuated LV
enlargement as indicated by significantly lower LV EDV and ESV. In addition, LV PWth,
which was significantly increased at the follow-up by myocardial infarction (1.06 ± 0.04 mm
and 0.91 ± 0.03 mm in MI and sham, respectively, p<0.05), was attenuated by treatment
(0.82 ± 0.04 mm, p<0.01 MI vs. MI+Val).
Echocardiography analyses of LV structure and function (S1 Table) confirmed CMR data,
showing additionally an increase in LV mass at 4 weeks post-surgery in MI-mice (175 ± 14
mg) compared to sham (94 ± 14 mg, p<0.001 MI vs. sham) that was attenuated by treatment
with valsartan (135 ± 9 mg, p<0.01 MI vs. MI+Val).
Regional LV function—Bull’s eye representation
During the follow-up, anterior myocardial infarction resulted in acute loss of LV systolic func-
tion and progression of LV impairment. At 24 hours after surgery, bull’s eye representation of
regional LV contractile function showed a reduced contraction of anterior, antero-septal and
lateral sectors from apex to mid papillary region (mid-apical in the following) in infarcted mice
RFAC in Myocardial Infarction
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(MI and MI+Val) compared to sham group (Fig 2). At 1-week post surgery, when the remodel-
ing process was ongoing, the progression of LV impairment was evident in both infarcted
groups. RFAC discriminated regional differences in MI+Val compared to MI mice, showing at
the mid-apical level a significant protective effect in terms of contraction property exerted by
valsartan on the posterior, inferior, septal, and antero-septal sectors (Fig 2). The higher degree
of preserved mid-apical function observed at 1 week in the treated group became more
Fig 1. Flow chart showing the experimental protocol with the number of animals used, died and included in the study.
doi:10.1371/journal.pone.0135778.g001
RFAC in Myocardial Infarction
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significant at 4 weeks, with a predominant localization to the posterior and inferior mid-apical
sectors (Fig 2).
Results of the non-infarcted free wall are shown in Table 1, where averages of mid-apical
RFAC of the inferior (iRFAC) and posterior (pRFAC) sectors and their mean (ipRFAC) are
presented. These indices showed significant difference between MI+Val and MI group in
regional function of remote non-infarcted tissue; on the contrary, global EF could not discrimi-
nate between the groups (Table 1). Power analysis showed that sample sizes of 12 per group
achieved 85% power to detect a difference of 14.0 in ipRFAC between MI and MI+Val groups
at 4 weeks (Table 1), with the observed group standard deviations of 10.4 and 17.3 and with a
significance level (α) of 0.05 in a pairwise comparison.
Left atrium remodeling
LA and LAA parameters in sham-operated mice remained almost unchanged from baseline to
follow-up (Table 2). On the contrary, LA remodeling was evident 1 week after surgery in both
infarcted groups with an increase of volumes in comparison with sham group and no signifi-
cant differences between MI and MI+Val group. At 4 weeks LA Vmin was significantly greater
in MI compared to MI+Val group.
Concurrently, LAA length increased at week 1 and 4 in MI compared to sham group and,
LAA duct contraction was significantly and progressively lost. At the follow-up, treatment sig-
nificantly preserved both parameters (Table 2, Fig 3).
Histopathology
Coronary artery ligation resulted in infarction with loss of cardiomyocytes and scar formation.
Four weeks after surgery, infarct size, determined by Sirius red staining, was clearly greater in
Table 1. Left ventricular global and regional function.
Mice iRFAC pRFAC ipRFAC LV EF LV EDV LV ESV
(%) (%) (%) (%) (μl) (μl)
Baseline 12 69 ± 1 75 ± 1 72 ± 1 65 ± 1 42 ± 2 15 ± 1
24h
Sham 12 71 ± 1 77 ± 1 74 ± 1 65 ± 1 38 ± 1 13 ± 1
MI and MI+Val 24 32 ± 2§§§ 31 ± 3§§§ 31 ± 2§§§ 37 ± 1§§§ 56 ± 1§§§ 35 ± 1§§§
MI 12 29 ± 3 27 ± 3 28 ± 3 37 ± 1 58 ± 2 37 ± 1
MI+Val 12 36 ± 4 35 ± 4 35 ± 4 38 ± 1 53 ± 2 33 ± 1
1w
Sham 12 74 ± 2 77 ± 1 75 ± 2 69 ± 1 41 ± 1 13 ± 1
MI 12 21 ± 3§§§ 18 ± 2§§§ 20 ± 3§§§ 29 ± 2§§§ 96 ± 6§§§ 69 ± 6§§§
MI+Val 12 34 ± 4** 31± 5* 32 ± 5** 34 ± 2 80 ± 4* 53 ± 4*
4w
Sham 12 74 ± 3 80 ± 2 77 ± 2 68 ± 2 47 ± 1 15 ± 1
MI 12 22 ± 3§§§ 17 ± 2§§§ 20 ± 2§§§ 26 ± 2§§§ 117 ± 8§§§ 87 ± 7§§§
MI+Val 12 38 ± 4** 30 ± 5** 34 ± 4** 32 ± 2 90 ± 5** 63 ± 5**
Cardiac magnetic resonance evaluation of regional and global left ventricle function at the baseline and in sham, MI and MI+Val mice included in the study
during the follow-up period (24 hours, 1 and 4 weeks). Values are presented as mean ± SEM.
* p<0.05 and
** p<0.01 vs. MI.
§§§ p<0.001 vs. Sham.
doi:10.1371/journal.pone.0135778.t001
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MI than in MI+Val mice (39.3 ± 2.2% vs. 32.9 ± 1.9%, p<0.05). No damage was observed in
sham mice (Fig 4).
MCSA increased 1.5-fold in MI vs. sham hearts, whereas valsartan treatment preserved it
almost entirely (MI vs. sham p<0.001; MI vs. MI+Val p<0.05; Fig 5A). Immunofluorescence
analysis for Ki-67 showed an increased cell and fibroblast proliferation in non-infarcted myo-
cardium in MI compared to sham group, which is almost completely abrogated by treatment
with valsartan (MI vs. sham and MI vs. MI+Val p<0.001; Fig 5B).
ICF showed a decreased collagen content in treated mice versus MI (p<0.001, MI vs. sham
andMI vs. MI+Val). LAA collagen content inMI group increased 1.4-fold compared to sham,
while treatment maintained it at the sham level (MI vs. sham andMI vs. MI+Val p<0.05; Fig 5C).
Fig 2. Bull’s eye representations of mean regional fractional area change (RFAC) in sham, MI and MI+Val groups at 24 hours, 1 and 4 weeks after
MI (n = 12/group). Slices from LV apex to the base are shown from the inner to the outer circle, whereas red and green tones indicate lower and higher RFAC
values (the color bar on the right shows the corresponding scale). • for 0.05<p<0.1, * for p<0.05, ** for p<0.01. Lat: lateral; Post: posterior; Inf: inferior; Sept:
septal; Ant-Sept: Antero-septal; Ant: anterior.
doi:10.1371/journal.pone.0135778.g002
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Gene expression
To find which genes were significantly modulated by valsartan, we performed a genome-wide
gene expression analysis comparing the 3 groups at the 4-week time point. The number of sig-
nificant genes by controlling the proportion of false discoveries, at a FDR<0.1 with a CI = 80%
in a multivariate permutation F test (p<0.002), was 248. The number of genes with a signifi-
cant difference (p<0.01, FC ±1.2) in any of the two relevant post-hoc pairwise comparisons
(MI vs. sham and MI vs. MI+Val) was 174 (out of 248): of these, respectively 27 and 53 genes
were significantly up- or down-regulated by valsartan with respect to MI mice (S2 Table).
The CLICK algorithm identified 2 clusters of genes, with an overall average homogeneity of
0.834 (Fig 6): (1) 112 genes that were significantly overexpressed in MI in comparison with
sham group and down-regulated in MI+Val with respect to MI mice (Fig 6A and 6C), and,
conversely, (2) 62 genes that were decreased in MI compared to sham group and up-regulated
in MI+Val with respect to MI mice (Fig 6B and 6D). Gene set enrichment analysis of these two
clusters (Table 3) indicated that valsartan significantly modulates a number of biological pro-
cesses in MI mice. In particular, cluster 1 was significantly enriched with genes belonging to
the GO categories of regulation of cell death and/or cell proliferation, cardiovascular develop-
ment, integrin-mediated signaling pathway, extracellular matrix (ECM) organization and/or
binding, response to stress, and calcium binding. Cluster 2 was enriched with genes belonging
to amino acid metabolism and establishment of localization (i.e. the directed movement of a
Table 2. LA and LAA remodeling following Myocardial Infarction.
Mice LA Vmin LA Vmax LA EF LAA length LAAduct FS
(μl) (μl) (%) (mm) (%)
Baseline 12 2.0 ± 0.1 4.7 ± 0.4 57.2 ± 1.7 3.5 ± 0.1 47.9 ± 2.3
24h
sham 12 2.1 ± 0.1 4.6 ± 0.3 53.6 ± 1.7 3.4 ± 0.1 51.4 ± 1.6
MI and MI+Val 24 2.9 ± 0.3 5.5 ± 0.4 48.9 ± 2.4 3.6 ± 0.1 41.3 ± 1.3§§§
MI 12 2.8 ± 0.6 5.6 ± 1.0 49.9 ± 2.4 3.5 ± 0.2 43.6 ± 1.8
MI+Val 12 2.9 ± 0.4 5.5 ± 0.4 48.3 ± 4.3 3.8 ± 0.1 38.9 ± 1.6
1w
sham 12 2.3 ± 0.1 4.9 ± 0.3 52.7 ± 1.6 3.5 ± 0.1 48.2 ± 3.1
MI 12 4.2 ± 0.3§§§ 7.6 ± 0.4§§§ 45.6 ± 2.9§ 4.2 ± 0.2§§§ 32.2 ± 6.2§§
MI+Val 12 3.7 ± 0.2 7.5 ± 0.6 50.8 ± 1.6 4.1 ± 0.1 30.8 ± 3.7
4w
sham 12 2.6 ± 0.2 5.6 ± 0.4 54.3 ± 1.2 3.5 ± 0.1 43.3 ± 2.0
MI 12 5.2 ± 0.7§§§ 8.8 ± 1.0§§§ 43.1 ± 2.1§§§ 4.8 ± 0.2§§§ 19.2 ± 3.8§§§
MI+Val 12 3.6 ± 0.3* 7.3 ± 0.4 50.1 ± 1.7** 4.0 ± 0.1*** 40.6 ± 2.0***
Echocardiographic evaluation of LA and LAA at baseline and during the follow-up (24 hours, 1 and 4 weeks) in sham, MI and MI+Val mice included in the
study.
Left Atrial Minimum Volume (LA Vmin); Left Atrium Maximum Volume (LA Vmax); Left Atrial Emptying Fraction (LA EF); Left Atrial Appendage Maximum
long axis (LAA length); Left Atrial Appendage duct diameter fractional shortening (LAA duct FS). Values are presented as mean ± SEM.
* p<0.05,
** p<0.01, and
*** p<0.001 vs. MI.
§ p<0.05,
§§ p<0.01 and
§§§ p<0.001 vs. Sham.
doi:10.1371/journal.pone.0135778.t002
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Fig 3. Echocardiographic evaluation of left atrium (LA) and left atrium appendage (LAA) by apical 4-chamber views, 4-weeks after surgery,
representative images. In upper panels, LA maximum area is shown in sham (A), MI (B) and MI+Val (C) mice. In lower panels, LAA long axis is shown in
sham (D), MI (E) and MI+Val (F) mice. LAAla: LAA long axis; LV: left ventricle; RA: right atrium.
doi:10.1371/journal.pone.0135778.g003
Fig 4. Representative photomicrographs of infarct size evaluated from the base (left) to the apex (right) by Sirius red stainingmeasured at 4 weeks
after surgery in sham, MI and MI+Val groups. Scale bar: 1 mm.
doi:10.1371/journal.pone.0135778.g004
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Fig 5. (A) Myocyte cross-sectional area (MCSA) in the remote left ventricle (LV) in sham and infarcted groups (n = 6/group). (B) Cell proliferation measured
as KI-67 positivity and proliferating fibroblasts detected by double labeling with KI-67 and vimentin. Cells proliferation was expressed as percentage of KI-67
positive cells over total cell number (nuclei), whereas fibroblasts proliferation was expressed as percentage of vimentin/KI-67 double-positive cells over
vimentin positive cells. (C) Representative immunofluorescence and quantification of collagen type I staining of the non-infarcted LV (upper panels) and of
appendage (lower panels) in sham, MI and MI+Val mice at 4 weeks post-surgery. Interstitial collagen fraction was measured as the percentage of area
occupied by collagen on total tissue area. Values are mean ± SEM. * p<0.05, *** p<0.001 vs. MI. (n = 6/group).
doi:10.1371/journal.pone.0135778.g005
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Fig 6. Clusters of genes significantly modulated by valsartan treatment after myocardial infarction.
(A) Heatmap and (C) mean expression pattern of cluster 1, i.e. genes overexpressed in MI vs. sham group
and down-regulated in MI+Val vs. MI mice. (B) Heatmap and (D) mean expression pattern of cluster 2, i.e.
genes that were decreased in MI vs. sham group and up-regulated in MI+Val vs. MI mice. In the heatmaps,
normalized expression values are mean-centered and represented with a green, black, and red color scale
RFAC in Myocardial Infarction
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cell, a protein complex or organelle to a specific location), and genes with relevant transferase
activity, for instance, for the glutathione metabolism.
Quantitative trait analysis showed strong negative correlations between expression levels of
several genes in cluster 1 and ipRFAC, with significant correlation coefficients ranging from
-0.67 to 0.94 (Table 4). Specifically, an inverse relationship with ipRFAC was observed for: (a)
ECM genes, included those involved in integrin signaling pathway; (b) genes related to cardiac
function and repair (cardiovascular system development); (c) genes that participate in calcium
cell signalling pathways by binding to Ca2+; and (d) stress response genes, in particular those
regulating cell death.
Discussion
Cardiac magnetic resonance imaging in cardiovascular research is generally used to measure
myocardial mass, LV volumes, or EF. Although such measures of global function are very use-
ful, in the MI setting, where contractile dysfunction is generally localized to specific coronary
territories, it is critically important to evaluate regional myocardial function.
We already reported the CMR regional quantification of LV function by RFAC analysis
where the LV cavity was divided into several regions and the RFAC computed for each sector
and clearly visualized in a "bull’s eye" format [12]. This approach, allowing the non-invasive
localization of the infarction and the accurate functional characterization of the post-ischemic
cardiac remodeling, has potential application for assessing the effectiveness of pharmacological
treatments or regenerative medicine interventions. To explore this idea, we investigated the
ability of RFAC in discriminating the effects of treatment with valsartan, a selective inhibitor of
AT1R, on LV regional endocardial wall motion and systolic function in mouse model of MI.
The choice of valsartan was motivated by the role of the renin—angiotensin—aldosterone sys-
tem (RAAS) in cardiovascular disease, whose activation results in increased serum level of
angiotensin II that perpetuates vasoconstriction, endothelial dysfunction, LV hypertrophy,
myocardial fibrosis and remodeling [24–26]. Modulation of the RAAS has long been acknowl-
edged as a target of pharmacological treatment for primary and secondary cardiovascular pre-
vention. Clinical evidence showed that long-term administration of RAAS blockers, such as
ACE inhibitors and angiotensin receptor blockers, plays a critical role in post-infarction LV
remodeling attenuating fibrosis in both infarcted and non-infarcted myocardium and conse-
quently promoting the improvement of heart function and survival [27, 28].
This paper, while confirming that RFAC is a sensitive and accurate tool for LV endocardial
wall motion characterization [12], clearly highlights the effectiveness of this regional index,
compared to global parameters, in discriminating qualitatively and quantitatively the effects of
pharmacological intervention on cardiac performance.
Throughout the follow-up, bull’s eye visualization showed that anterior myocardial infarc-
tion resulted in acute loss of LV systolic function and progression of LV impairment. The
expansion of damaged myocardium affected not only apical and anterior sectors, but also the
inferior and posterior mid-papillary regions, indicating a progressive loss of contraction in
remote non-infarcted tissue probably as a result of LV stiffness and remodeling. Most interest-
ingly, RFAC analysis accurately located the regions where valsartan exerted its protective effect,
highlighting the drug efficacy in improving contractile function and reducing maladaptive
remodeling. At 1-week post surgery, when remodeling was still progressing, even in the
(green indicates below, black equal to, and red above the mean). In the graphs B andD, each cluster is
represented by the mean expression pattern over all the genes assigned to it for each sample; error bars
denote ± 1 SD (n = 6/group).
doi:10.1371/journal.pone.0135778.g006
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Table 3. GO enrichment analysis of differentially expressed gene clusters.
GO GO term pcorr Gene List
Cluster_1
BP regulation of cell death 0.001 Ptgis, Plcg2, Nox4, Anxa5, Prmt2, Ankrd1, Cd44, Ctgf, Phlda3, Gpx1, Nupr1, Actn4,
Crlf1, Mllt11, F2r, Timp1, Prnp, Sox9, Mmp2, Comp
cellular component organization 0.002 Prmt2, Lox, Nav1, Efhd1, Kctd1, Sulf1, Gpx1, F2r, Sox9, Mmp2, Acta1, Dpysl3, Nox4,
Mgp, Anxa5, Hspa2, Xirp2, Cd44, Pdlim7, Mfap5, Ctgf, Col4a1, Nbl1, Nupr1, Actn4,
2610039C10Rik, Arpc5, Prnp, Adamts2, Comp
system development 0.001 Plcg2, Odc1, Lox, Nav1, Efhd1, Sulf1, Gpx1, Col8a1, F2r, Timp1, Sox9, Mmp2, Acta1,
Ecm1, Dpysl3, Nox4, Mgp, Srpx2, Ankrd1, Cd44, Myh7, Ctgf, Col4a1, Sparc, Nbl1,
Serpinf1, Nupr1, Igfbp7, Adamts2, Comp
regulation of angiogenesis 0.025 Ptgis, Serpinf1, Srpx2, Anxa3, Sulf1, Ecm1
regulation of developmental process 0.002 Ptgis, Mgp, Srpx2, Anxa3, Ankrd1, Sulf1, Cd44, Pdlim7, Ctgf, Nbl1, Gpx1, Serpinf1,
Nupr1, Med10, Timp1, Palmd, Sox9, Ecm1, Dpysl3
cardiovascular system development 0.004 Nox4, Gpx1, Srpx2, Col8a1, Lox, Ankrd1, Myh7, Col4a1, Ctgf, Sox9, Mmp2, Ecm1
skeletal muscle ﬁber development 0.035 Gpx1, F2r, Col4a1, Acta1
muscle organ development 0.024 Gpx1, Nupr1, Ankrd1, F2r, Myh7, Col4a1, Acta1
anatomical structure formation involved in
morphogenesis
0.041 Gpx1, Srpx2, Col8a1, Meox1, Cd44, Col4a1, Ctgf, Sox9, Mmp2, Acta1, Ecm1
tissue development 0.002 Mgp, Ankrd1, Sulf1, Myh7, Cd44, Ctgf, Col4a1, Gpx1, Nupr1, F2r, Sox9, Mmp2, Acta1,
Ecm1, Adamts2, Comp
cell adhesion 0.002 Srpx2, Igfbp7, Col8a1, Itgbl1, Wisp2, Svep1, Cd44, Mfap4, Itga11, Col16a1, Ctgf, Sox9,
Comp
integrin-mediated signaling pathway 0.012 Cib1, Itgbl1, Itga11, Ctgf, Adamts2
regulation of cellular component movement 0.002 Nox4, Nbl1, Srpx2, Actn4, Anxa3, Sulf1, Timp1, F2r, Sox9, Ecm1, Dpysl3
regulation of peptidase activity 0.002 Gpx1, Serpinf1, Pi16, Timp1, F2r, Cd44, Pcolce, Ctgf, Ecm1, Pcolce2
regulation of cell proliferation 0.002 Odc1, Nox4, Comt, Wisp2, Sulf1, Vsig4, Ctgf, Sparc, Gpx1, Serpinf1, Nupr1, Crlf1, Cib1,
F2r, Prnp, Sox9, Ecm1
negative regulation of cell proliferation 0.002 Nox4, Comt, Serpinf1, Nupr1, Cib1, Wisp2, Sulf1, Vsig4, F2r, Prnp, Sox9
negative regulation of biological process 0.001 Plcg2, Ptgis, Prmt2, Lmcd1, Kctd1, Sulf1, Vsig4, Phlda3, Gpx1, Med10, Cib1, F2r, Timp1,
Sox9, Mmp2, Ecm1, Dpysl3, Nox4, Anxa5, Comt, Wisp2, Ankrd1, Rangap1, Cd44, Nbl1,
Serpinf1, Nupr1, Crlf1, Actn4, Pde1c, Prnp, Comp
regulation of multicellular organismal process 0.001 Ptgis, Mgp, Anxa5, Srpx2, Anxa3, Lmcd1, Ankrd1, Sulf1, Vsig4, Cd44, Pdlim7, Myh7,
Ctgf, Nbl1, Gpx1, Serpinf1, Nupr1, F2r, Timp1, Prnp, Sox9, Mmp2, Ecm1, Dpysl3
positive regulation of cellular process 0.001 Ptgis, Odc1, Prmt2, Lmcd1, Sulf1, Phlda3, Gpx1, Med10, Col8a1, F2r, Sox9, Mmp2,
Ecm1, Dpysl3, Fbln2, Nox4, Anxa5, Srpx2, Comt, Hspa2, Anxa3, Ankrd1, Meox1, Cd44,
Pdlim7, Ctgf, Nbl1, Serpinf1, Nupr1, Crlf1, Actn4, Mllt11
positive regulation of signal transduction 0.018 Ptgis, Nox4, Gpx1, Crlf1, Lmcd1, Ankrd1, Sulf1, F2r, Cd44, Ctgf, Sox9, Ecm1
response to stress 0.038 Ptgis, Anxa5, Comt, Anxa3, Lox, Hspa2, Cd44, F13a1, Phlda3, Gpx1, Nupr1, Cib1, Lyz1,
Lyz2, F2r, Ino80c, Prnp, Mmp2, Ecm1
extracellular matrix organization 0.002 Lox, Sulf1, Mfap5, Ctgf, Sox9, Adamts2, Comp
sulfur compound metabolic process 0.002 Chst7, Nox4, Gpx1, Hagh, Dcn, Sulf1, Bgn
MF glycosaminoglycan binding 0.001 Dcn, Cd44, Pcolce, Bgn, Prelp, Ctgf, Comp, Pcolce2, Dpysl3, Fstl1
calcium ion binding 0.001 Mgp, Anxa5, Anxa3, Efhd1, S100a11, Sulf1, Creld1, Sparc, Actn4, Cib1, Emr1, Cd248,
Svep1, Comp, Fstl1
extracellular matrix binding 0.002 Fbln2, Dcn, Bgn, Sparc, Ecm1
collagen binding 0.023 Dcn, Pcolce, Comp, Pcolce2
Cluster_2
BP cellular modiﬁed amino acid metabolic process 0.006 Gstm1, Stat5a, Gstk1, Mat2a, Ccbl2
carboxylic acid metabolic process 0.007 Gstm1, Stat5a, Gstk1, Acot7, Mat2a, Pkm2, Ccbl2, Crat, Acot1
establishment of localization 0.035 Abcc9, Ndufs2, Adhfe1, Crat, Gga2, Nudc, Fxyd1, Ano10, Bves, Sdhc, Tmem38a, Agtr1a,
Stat5a, Slc2a4, Vdac1, Etfb, Osbpl3
(Continued)
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presence of many processes that could act as confounding factors (such as inflammation,
angiogenesis and granulation tissue formation), RFAC was able to show significant differences
in mid-apical regions between MI and MI+Val groups. At 4 weeks, when the remodeling was
almost complete, differences between groups became even more significant and localized
mostly in the mid apical free wall region. Tissue analysis of these latter zones showed, at the cel-
lular level, attenuated myocyte hypertrophy, reduction in number of proliferating fibroblast
and decreased deposition of interstitial collagen, which were associated with an overall benefi-
cial effect on ventricular remodeling and with improved heart function.
The protective effect documented by CMR is consistent with results from genome-wide
gene expression profiling. This analysis shows that valsartan exerted its function by modulating
target genes involved in several processes such as cell death and proliferation, Ca2+ binding,
integrin-mediated signaling, ECM organization and response to stress, which were significantly
altered by infarct and almost restored to the normal level by valsartan treatment (Fig 6). Coher-
ently, several genes, belonging to the above biological processes and molecular functions,
showed an inverse correlation with RFAC, i.e. the greater the LV regional wall motion and con-
traction, the lower their expression. Indeed, cardiac development, Ca2+ signaling, ECM, and
stress response related genes showed higher expression in the LV remote non-infarcted free
wall of sham mice, intermediate in the valsartan-treated MI group, and lower in untreated MI
mice, suggesting that infaction induces compensatory/repair pathways which are attenuated by
valsartan protective effects.
Importantly, genes playing key roles in the development of the pro-fibrotic process were
massively upregulated in remote non-infarcted myocardium in the MI group and, consistent
with a recent report [29], significantly modulated by Valsartan. In particular, post-MI remodel-
ing was associated with a complex response of genes encoding ECM-related molecules, such as
Tissue Inhibitor of Metalloproteinases-1 (TIMP1) and Fibulin 2. Elevated TIMPs have been
demonstrated in the infarcted heart [30, 31] and contributed to collagen accumulation in the
process of scar formation probably by stimulating fibroblast growth [30, 32, 33]. Thus, TIMP1
over-expression may favor cardiac fibrosis not only by inhibiting matrix metalloproteinase, but
also by independent direct pro-fibrotic mechanisms. Fibulin 2 is an ECM protein that can
interact with a wide range of ECM proteins and be incorporated into various extracellular
structures. A number of observations [34, 35] suggest that Fibulin 2 plays significant roles in
embryonic development and tissue remodeling. Following valsartan treatment, this group of
genes was negatively regulated. This data, together with the evidence of the anti-hypertrophic
and anti-fibrotic effects observed by tissue analysis, led us to hypothesize that these factors
likely participate in convergent pathways. Further investigation will delineate their specific
contributions and may provide novel therapeutic targets.
Clinical evidences show that infarction affects both LV and LA and the ability of the latter
to respond to a decrease in LV compliance by increasing its size [36]. Indeed, after infarction,
LV end-diastolic pressure and wall tension increase [37] and, consequently, LA enlarges to
maintain adequate LV filling: these modifications, indexed by LA volume quantitation, can be
used as a sensitive and specific tool for the detection of LV dysfunction [16, 38, 39]. The
Table 3. (Continued)
GO GO term pcorr Gene List
MF transferase activity, transferring alkyl or aryl
(other than methyl) groups
0.006 Gstm1, Gstk1, Mat2a, Gstm7
GO: Gene Ontology; BP: biological process; MF: molecular function; pcorr: corrected p-value
doi:10.1371/journal.pone.0135778.t003
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Table 4. Correlations between gene expression in specified GO gene sets and ipRFAC.
GO terms Gene Symbol r p
Integrin-mediated signaling pathway and/or Extracellular matrix organization & binding Bgn -0.943 < 1 × 10−7
Itgbl1 -0.929 1.00 × 10−7
Ctgf -0.922 1.00 × 10−7
Fbln2 -0.915 3.00 × 10−7
Mfap5 -0.909 5.00 × 10−7
Adamts2 -0.888 1.90 × 10−6
Itga11 -0.86 9.40 × 10−6
Ecm1 -0.812 7.57 × 10−5
Comp -0.812 7.52 × 10−5
Dcn -0.798 1.25 × 10−4
Sulf1 -0.759 4.11 × 10−4
Lox -0.756 4.49 × 10−4
Sparc -0.756 4.46 × 10−4
Cib1 -0.74 6.86 × 10−4
Sox9 -0.676 2.88 × 10−3
Cardiovascular system development Ctgf -0.922 1.00 × 10−7
Nox4 -0.886 2.30 × 10−6
Ankrd1 -0.884 2.60 × 10−6
Col8a1 -0.878 3.60 × 10−6
Gpx1 -0.836 2.93 × 10−5
Srpx2 -0.826 4.48 × 10−5
Ecm1 -0.812 7.57 × 10−5
Mmp2 -0.811 7.94 × 10−5
Myh7 -0.792 1.48 × 10−4
Lox -0.756 4.49 × 10−4
Sox9 -0.676 2.88 × 10−3
Col4a1 -0.619 8.05 × 10−3
Calcium ion binding Svep1 -0.867 6.80 × 10−6
Fstl1 -0.833 3.32 × 10−5
Anxa3 -0.823 5.00 × 10−5
Comp -0.812 7.52 × 10−5
Efhd1 -0.797 1.27 × 10−4
Mgp -0.793 1.45 × 10−4
Cd248 -0.793 1.46 × 10−4
S100a11 -0.782 2.08 × 10−4
Emr1 -0.773 2.78 × 10−4
Sulf1 -0.759 4.11 × 10−4
Sparc -0.756 4.46 × 10−4
Cib1 -0.74 6.86 × 10−4
Creld1 -0.728 9.22 × 10−4
Actn4 -0.722 1.07 × 10−3
Anxa5 -0.708 1.48 × 10−3
(Continued)
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beneficial effects on LV global volumes and RFAC exerted by valsartan were confirmed by the
echocardiographic analysis of LA volume. Concurrently to LA enlargements, also LA append-
age increased in lengths and this process appeared to progress over time. Tissue analyses
revealed that the increase in dimension was accompanied to an increase in fibrosis in MI
group, probably as direct consequence of LV dysfunction and hemodynamic atrial overload
Table 4. (Continued)
GO terms Gene Symbol r p
Regulation of cell death Ctgf -0.922 1.00 × 10−7
Timp1 -0.895 1.20 × 10−6
Nox4 -0.886 2.30 × 10−6
Ankrd1 -0.884 2.60 × 10−6
Cd44 -0.849 1.66 × 10−5
Gpx1 -0.836 2.93 × 10−5
Crlf1 -0.834 3.12 × 10−5
Plcg2 -0.832 3.38 × 10−5
Nupr1 -0.824 4.84 × 10−5
Comp -0.812 7.52 × 10−5
Mmp2 -0.811 7.94 × 10−5
Phlda3 -0.8 1.14 × 10−4
Ptgis -0.798 1.23 × 10−4
Mllt11 -0.784 1.92 × 10−4
Prmt2 -0.777 2.40 × 10−4
Actn4 -0.722 1.07 × 10−3
Prnp -0.711 1.38 × 10−3
Anxa5 -0.708 1.48 × 10−3
Sox9 -0.676 2.88 × 10−3
F2r -0.667 3.45 × 10−3
Response to stress Comt -0.866 7.10 × 10−6
Cd44 -0.849 1.66 × 10−5
Lyz1 -0.849 1.60 × 10−5
Gpx1 -0.836 2.93 × 10−5
Nupr1 -0.824 4.84 × 10−5
Anxa3 -0.823 5.00 × 10−5
Lyz2 -0.814 6.97 × 10−5
Ecm1 -0.812 7.57 × 10−5
Mmp2 -0.811 7.94 × 10−5
Phlda3 -0.8 1.14 × 10−4
Ptgis -0.798 1.23 × 10−4
Lox -0.756 4.49 × 10−4
Cib1 -0.74 6.86 × 10−4
F13a1 -0.717 1.19 × 10−3
Prnp -0.711 1.38 × 10−3
Anxa5 -0.708 1.48 × 10−3
Hspa2 -0.705 1.56 × 10−3
Ino80c -0.685 2.39 × 10−3
F2r -0.667 3.45 × 10−3
r: correlation coefﬁcient; p: parametric p-value
doi:10.1371/journal.pone.0135778.t004
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[40, 41]. Treatment with valsartan attenuated LV dysfunction, and this was associated with
regression of atrial and appendage myocardium remodeling.
LA volume increase reflects the average effect of LV filling pressures over time [36, 42] and
is an index of ventricular dysfunction. We also observe that, for murine MI model, the LA vol-
ume increase is a more sensitive marker of LV dysfunction than the posterior wall thickness,
which showed only minimal changes.
In summary, our study provides strong evidence that in the evaluation of a pharmacological
therapy following infarction, RFAC can detect (and localize) much subtler changes in cardiac
performance than EF, which is the weighted average of the RFAC on the whole ventricle vol-
ume. Comparing RFAC with strain echocardiography could add more information on regional
function and/or the benefits of RFAC, but unfortunately this echocardiographic tool is unavail-
able to us.
Conclusions
RFAC index accurately monitored the efficacy of a pharmacological treatment during the fol-
low-up and indicated the inferior and posterior sectors of the LV remote non-infarcted free
wall as those where valsartan exerted a protective effect on contraction. This data was sup-
ported by evidences at the cellular level indicating attenuated myocyte hypertrophy, reduction
in number of proliferating fibroblast and decreased deposition of fibrillar collagen, and by
modulation of relevant gene pathways. The overall beneficial effect on ventricular remodeling
was additionally confirmed by attenuation of LA enlargement.
Taken together, these data indicate that RFAC index could be applied in studies assessing
localized and global wall motion differences secondary to standard pharmacological treatment
in a mouse model of infarction.
This information might serve to provide a novel view on the evaluation of tissue injury and
its response to ischemia, and contribute to gain new insights into the evaluation of new thera-
pies, which in the future could be translated to acute MI patients.
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